Thomas A. West

September 30, 2026

CeriBell Gets FDA Clearance for New EEG Analysis Tools. CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.

October 16, 2026

Truist Securities raises SI-BONE price target to $25. Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.

September 29, 2026

Medical device growth debate touches Inogen sector. A recent Yahoo article examined whether ResMed or Stryker offers a better path to capture medical device growth. Inogen operates in the same medical device market, so the analysis is relevant to how the sector is being evaluated. The discussion may influence how market participants view companies that provide portable oxygen solutions.

October 13, 2026

Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.